G18 : The FXR agonist PX20606 reduces liver damage, fibrosis and portal hypertension in cirrhotic rats

Schwabl, Philipp; Hambruch, Eva; Payer, BA; Schubert, T.L.; Strobel, B; Fida, Shahnaz; Wagner, Michael; Garnys, L; Trauner, Michael; Peck‐Radosavljevic, Markus; Kremoser, Claus; Reiberger, T

doi:10.1016/s0168-8278(15)30106-9

Cited by 2 publications

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The steroidal and non-steroidal FXR ligands have shown beneficial effects on portal hypertension in preclinical mouse models of pre- and intrahepatic portal hypertension [57,58,59]. These effects may be mediated by reducing intrahepatic resistance by promoting nitric oxide production, its anti-fibrotic effects but also potential impact on gut integrity reducing bacterial translocation.…”

Section: Potential Further Applications For Fxr Ligandsmentioning

confidence: 99%

Farnesoid X Receptor Agonists and Other Bile Acid Signaling Strategies for Treatment of Liver Disease

Halilbasic

Fuchs

Traussnigg

et al. 2016

Dig Dis

View full text Add to dashboard Cite

The intracellular nuclear receptor farnesoid X receptor (FXR) and the transmembrane G protein-coupled receptor 5 (TGR5) respond to bile acids (BAs) by activating transcriptional networks and/or signaling cascades. These cascades affect the expression of a great number of target genes relevant for BA, cholesterol, lipid and carbohydrate metabolism, as well as genes involved in inflammation, fibrosis and carcinogenesis. FXR activation in the liver tissue and beyond, such as the gut-liver axis, kidney and adipose tissue, plays a role in metabolic diseases. These BA receptors activators hold promise to become a new class of drugs to be used in the treatment of chronic liver disease, hepatocellular cancer and extrahepatic inflammatory and metabolic diseases. This review discusses the relevant BA receptors, the new drugs that target BA transport and signaling and their possible applications.

show abstract

Section: Potential Further Applications For Fxr Ligandsmentioning

confidence: 99%